Women of childbearing age. Discontinue use if muscle pain of calf, back or entire body; serum CK conc become markedly elevated or if myopathy occurs; if increases in AST or ALT conc of ≥3x ULN persist. Perform LFTs before &, at 6- & 12-wk after initiation of therapy & periodically thereafter. Increased risk of rhabdomyolysis in patients w/ renal or hepatic impairment, chronic alcoholism, hypothyroidism, using high doses of rosuvastatin, geriatric patients. Temporarily withhold in patients experiencing an acute, serious condition suggestive of myopathy or predisposing to the development of acute renal failure secondary to rhabdomyolysis (eg, hypotension, sepsis, dehydration, major surgery, trauma, severe metabolic, endocrine or electrolyte disorders, uncontrolled seizures). Asian patients. Consider dose reduction in patients who have unexplained persistent proteinuria during routine urinalysis testing. Concomitant use w/ any statins or agents used to lower cholesterol levels or drugs that may decrease levels or activity of endogenous steroid hormones (eg, ketoconazole, spironolactone, cimetidine); digoxin, warfarin; certain azole antifungals (eg, ketoconazole, itraconazole), macrolides (eg, erythromycin, clarithromycin), HIV PIs (eg, indinavir, ritonavir, nelfinavir, saquinavir), verapamil, diltiazem, gemfibrozil, nicotinic acid, cyclosporine & amiodarone; colchicine (especially in elderly or renal impairment patients).
Sign Out
